At the time of writing, Moderna Inc [MRNA] stock is trading at $43.0, up 2.80%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The MRNA shares have gain 27.07% over the last week, with a monthly amount glided 40.94%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Jefferies started tracking the stock with Hold rating on December 12, 2025, and set its price target to $30. On March 13, 2025, Citigroup initiated with a Neutral rating and assigned a price target of $40 on the stock. Barclays downgraded its rating to a Equal Weight and decreased its price target to $45 on February 18, 2025. Goldman downgraded its rating to a Neutral and reduced its price target to $51 on January 29, 2025. Argus downgraded its rating to Hold for this stock on December 18, 2024.
For the past year, the stock price of Moderna Inc fluctuated between $22.28 and $45.40. Currently, Wall Street analysts expect the stock to reach $30.73 within the next 12 months. Moderna Inc [NASDAQ: MRNA] shares were valued at $43.0 at the most recent close of the market. An investor can expect a potential drop of -28.53% based on the average MRNA price forecast.
Analyzing the MRNA fundamentals
According to Moderna Inc [NASDAQ:MRNA], the company’s sales were 2.23B for trailing twelve months, which represents an -45.44% plunge. Gross Profit Margin for this corporation currently stands at 0.12% with Operating Profit Margin at -1.56%, Pretax Profit Margin comes in at -1.42%, and Net Profit Margin reading is -1.4%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.31 and Total Capital is -0.33. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Moderna Inc [NASDAQ:MRNA] has a current ratio of 3.93. In addition, the Quick Ratio stands at 3.73 and the Cash Ratio stands at 0.67. Considering the valuation of this stock, the price to sales ratio is 7.53, the price to book ratio is 1.80.
Transactions by insiders
Recent insider trading involved AFEYAN NOUBAR, Director, that happened on Dec 11 ’25 when 23853.0 shares were sold. Affiliate, Flagship Pioneering Inc. completed a deal on Dec 11 ’25 to buy 23853.0 shares. Meanwhile, Director Hussain Abbas sold 504.0 shares on Dec 09 ’25.
